Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TNIK-IN-3 is a highly potent and orally active inhibitor of Traf2- and Nck-interacting protein kinase (TNIK). It exhibits a strong selectivity for TNIK with an IC50 value of 0.026 μM. Additionally, TNIK-IN-3 demonstrates inhibitory activity against Flt4 (IC50 = 0.030 μM), Flt1 (IC50 = 0.191 μM), and DRAK1 (IC50 = 0.411 μM). This compound holds potential for carrying out research on colorectal cancer (CRC) [1].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,320 | 现货 | ||
5 mg | ¥ 3,310 | 现货 | ||
10 mg | ¥ 4,830 | 现货 | ||
25 mg | ¥ 7,590 | 现货 | ||
50 mg | ¥ 9,870 | 现货 | ||
100 mg | ¥ 13,800 | 现货 | ||
500 mg | ¥ 27,700 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,650 | 现货 |
产品描述 | TNIK-IN-3 is a highly potent and orally active inhibitor of Traf2- and Nck-interacting protein kinase (TNIK). It exhibits a strong selectivity for TNIK with an IC50 value of 0.026 μM. Additionally, TNIK-IN-3 demonstrates inhibitory activity against Flt4 (IC50 = 0.030 μM), Flt1 (IC50 = 0.191 μM), and DRAK1 (IC50 = 0.411 μM). This compound holds potential for carrying out research on colorectal cancer (CRC) [1]. |
体外活性 | TNIK-IN-3 (compound 21k) inhibits Aurora-A, GCK, and MLK3 with IC 50 s of 0.517 μM, 3.657 μM, and 4.552 μM, respectively [1]. TNIK-IN-3 (0.1-100 μM; 3 days) inhibits the viability of HCT116 and DLD-1 cells, with IC 50 s of 4.26 μM and 8.00 μM, respectively [1]. TNIK-IN-3 (2.5-40 μM; 10 days) dose-dependently inhibits the colony formation of HCT116 and DLD-1 cells [1]. TNIK-IN-3 (5-20 μM; 48 h) inhibits the HCT116 and DLD-1 cell migration[1]. TNIK-IN-3 (5-40 μM; 48 h) dose-dependently inhibits the expression ofLRP5 and LRP6 proteins, Wnt target genes AXIN2 and c-Myc in HCT116 cells [1]. TNIK-IN-3 (5-20 μM; 48 h) significantly suppresses the phosphorylation of JNK1/2 in Hela cells [1]. Cell Viability Assay [1] Cell Line: HCT116 and DLD-1 cells Concentration: 0.1-100 μM Incubation Time: 3 days Result: Inhibited cell viability in a dose-dependent manner. Cell Viability Assay [1] Cell Line: HCT116 cells Concentration: 5, 10, 20, 40 μM Incubation Time: 48 hours Result: Inhibited the expression of Wnt target genes AXIN2 and c-Myc, LRP5 and LRP6 proteins. |
体内活性 | TNIK-IN-3 (compound 21k) (100-150 mg/kg; p.o. twice daily for 18 days) dose-dependently inhibits tumor growth[1]. Animal Model: Six-week-old female NOD-SCID mice were injected with HCT116 cells [1] Dosage: 100, 150 mg/kg Administration: P.o. twice daily for 18 days Result: Significantly inhibited tumor growth at a dose of 150 mg/kg. No obvious weight loss and no other side effects were observed. |
分子量 | 387.41 |
分子式 | C23H18FN3O2 |
CAS No. | 2754265-25-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 75.6 mg/mL (195.1 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5812 mL | 12.9062 mL | 25.8124 mL | 64.5311 mL |
5 mM | 0.5162 mL | 2.5812 mL | 5.1625 mL | 12.9062 mL | |
10 mM | 0.2581 mL | 1.2906 mL | 2.5812 mL | 6.4531 mL | |
20 mM | 0.1291 mL | 0.6453 mL | 1.2906 mL | 3.2266 mL | |
50 mM | 0.0516 mL | 0.2581 mL | 0.5162 mL | 1.2906 mL | |
100 mM | 0.0258 mL | 0.1291 mL | 0.2581 mL | 0.6453 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
TNIK-IN-3 2754265-25-1 Cytoskeletal Signaling Stem Cells Wnt/beta-catenin TNIK IN 3 TNIKIN3 Inhibitor inhibitor inhibit